BOSTON (MarketWatch) -- Pfizer shares lost ground Tuesday, following the release of mixed preliminary clinical data for a proposed follow-on product to its blockbuster cholesterol drug Lipitor. Shares ...

With it exclusive window on cholesterol drug Lipitor long closed, Pfizer is looking to the post-Lipitor world. WSJ's Spencer Jakab visits Mean Street to make the case that the company's future is ...

Pfizer Inc is urging the U.S. Supreme Court to allow it to remove lawsuits by about 4,800 women who claim they developed diabetes as a result of taking Lipitor, its blockbuster anti-cholesterol drug, ...